Financial Performance - The company's operating revenue for 2024 reached ¥712,904,207.78, representing a 42.72% increase compared to ¥499,500,775.41 in 2023[22]. - The net profit attributable to shareholders for 2024 was ¥104,951,340.17, an increase of 87.47% from ¥58,874,449.10 in the previous year[22]. - The basic earnings per share for 2024 was ¥0.52, reflecting an 85.71% increase from ¥0.29 in 2023[22]. - The total assets at the end of 2024 were ¥4,805,251,739.12, a slight decrease of 0.05% from ¥4,810,426,435.78 at the end of 2023[22]. - The net assets attributable to shareholders decreased by 0.97% to ¥4,491,208,199.82 at the end of 2024 from ¥4,538,022,505.51 in 2023[22]. - The company reported a net cash flow from operating activities of -¥13,649,510.39 in 2024, a significant decline of 123.82% compared to ¥57,310,770.18 in 2023[22]. - The gross profit margin for the overall business in 2024 was 11.11%, up from 3.05% in 2023[94]. - The revenue from erythritol products was ¥515,434,856.5 in 2024, with a gross profit margin of 8.28%[92]. - The revenue from blended sweeteners increased by 90.70% to ¥105,323,176.5 in 2024, with a gross profit margin of 17.21%[92]. - The revenue from direct sales in 2024 was ¥218,508,291.7, with a gross profit margin of 16.45%[94]. - The revenue from the food manufacturing sector amounted to ¥698,508,291.94, accounting for 97.98% of total revenue, with a year-on-year growth of 44.70%[124]. Market and Product Development - The company aims to enhance its product offerings in the functional sugar market, focusing on low-calorie sweeteners[16]. - The company is actively pursuing market expansion strategies to increase its footprint in the health food sector[16]. - The company has plans for new product development in response to growing consumer demand for healthier alternatives[16]. - The company is committed to improving its extraction rates and conversion rates in the production of functional sugars[16]. - The company is focusing on new product development in areas such as allulose and high-quality stevia, investing significant R&D resources[116]. - The company aims to accelerate the commercialization of new products and technologies to expand into new business areas[121]. - The company plans to enhance its product offerings by promoting high-quality stevia and accelerating the production of allulose and tagatose[185]. Industry Trends and Challenges - The global demand for erythritol is projected to reach 238,000 tons in 2024, with a compound annual growth rate (CAGR) of 22% from 2020 to 2024[34]. - The global erythritol market is expected to reach a value of $1.17426 billion by 2025, with a CAGR of 17.34% from 2025 to 2030[34]. - The erythritol industry is currently experiencing a phase of market restructuring, with many new entrants facing challenges in product quality and competition[42]. - The European Union initiated anti-dumping investigations against Chinese erythritol products, with potential duties ranging from 34.4% to 233.3%[43]. - The company faces risks from intensified industry competition and potential fluctuations in downstream customer demand, which could impact sales and pricing[179]. Governance and Compliance - The company’s financial report is guaranteed to be true, accurate, and complete by the company's management, ensuring accountability for any misrepresentation[3]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective internal control and operational standards[193]. - The board of directors consists of 9 members, including 3 independent directors, and operates through specialized committees to fulfill its responsibilities[195]. - The supervisory board is composed of 3 members, including 1 employee representative, and effectively supervises major company matters and compliance[196]. - The controlling shareholder exercises rights and obligations lawfully, without interfering in the company's decision-making or operations[197]. - The company respects and protects the rights of stakeholders, ensuring a balance of interests among shareholders, employees, and society[199]. - There have been no instances of non-compliance in governance, such as providing undisclosed information to major shareholders[199]. Research and Development - Research and development (R&D) expenditure amounted to 41,232,951.56 yuan, representing 5.78% of operating revenue, a decrease from 10.14% in the previous year[142]. - The number of R&D personnel increased by 9.26% to 59, with a notable rise in the proportion of personnel aged 40 and above by 44.44%[142]. - The company has developed core patents for the fermentation extraction of erythritol, achieving industry-leading conversion rates[115]. - The company is developing new products such as high-efficiency erythritol fermentation strains, aiming to increase production yield and conversion rates by over 5%[144]. - The company has successfully developed high-quality steviol glycosides, which has reduced R&D expenses significantly[143]. Cash Management and Fund Utilization - The company has raised a total of 368,570.53 million CNY from its initial public offering, with a net amount of 354,664.46 million CNY after deducting issuance costs of 13,906.07 million CNY[165]. - The company plans to use up to 330,000.00 million CNY of temporarily idle raised funds for cash management, ensuring it does not affect the construction of investment projects[165]. - The company has not encountered any issues or other situations regarding the use of raised funds during the reporting period[167]. - The company has not sold any major assets during the reporting period[170]. - The company has utilized a total of 126,026.24 million yuan of its own funds for investment[167]. Strategic Initiatives - The company will implement a threefold optimization strategy in sales, focusing on market diversification, small packaging product promotion, and enhancing brand influence[175]. - The company is committed to developing new products, including tagatose and sialic acid, to diversify its product line and reduce operational risks associated with a narrow product focus[176]. - The company will enhance its safety production measures and environmental governance to ensure stable operations and promote low-carbon production processes[177]. - The company plans to strengthen its innovation system by integrating customer needs with technological advancements, aiming for a closed-loop mechanism from demand to commercialization[176].

Financial Performance - The company's revenue for Q1 2024 reached ¥191,894,599.16, representing a 65.03% increase compared to ¥116,276,458.04 in the same period last year[4] - Net profit attributable to shareholders was ¥24,247,672.28, a significant increase of 210.54% from ¥7,808,194.59 year-on-year[4] - Basic and diluted earnings per share both increased to ¥0.12, reflecting a 200.00% rise from ¥0.04 in the same quarter last year[4] - Total operating revenue for the current period reached ¥191,894,599.16, a significant increase from ¥116,276,458.04 in the previous period, representing a growth of approximately 64.8%[23] - Net profit for the current period was ¥24,247,672.28, compared to ¥7,808,194.59 in the previous period, reflecting a growth of approximately 210.5%[24] Cash Flow - The net cash flow from operating activities surged by 744.81% to ¥22,158,704.92, up from ¥2,622,930.65 in the previous year[4] - Total cash inflow from operating activities reached 202,928,457.01 yuan, up from 143,143,501.00 yuan, reflecting a growth of 41.6%[26] - Cash outflow for operating activities was 180,769,752.09 yuan, compared to 140,520,570.35 yuan, an increase of 28.6%[26] - Net cash flow from investing activities was -32,224,720.95 yuan, an improvement from -328,183,999.71 yuan in the previous period[27] - The company received 18,871,599.36 yuan in tax refunds, up from 12,477,423.01 yuan, indicating a growth of 51.1%[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,879,388,138.47, a 1.49% increase from ¥4,807,533,905.12 at the end of the previous year[4] - Current assets totaled ¥351,020,607.19, up from ¥321,813,853.97, which is an increase of approximately 9.0%[21] - The total liabilities increased to ¥320,010,491.34 from ¥272,403,930.27, indicating a rise of about 17.5%[22] - The total equity attributable to the parent company increased to ¥4,559,377,647.13 from ¥4,535,129,974.85, a growth of about 0.5%[22] Operating Costs and Expenses - The company reported a 44.95% increase in operating costs, primarily due to higher sales volume[8] - Total operating costs amounted to ¥194,873,387.02, up from ¥135,685,668.54, indicating an increase of about 43.5%[23] - Research and development expenses rose by 34.31%, indicating the company's commitment to enhancing competitiveness through increased market expansion and R&D investment[8] - The company's research and development expenses were ¥15,833,077.03, compared to ¥11,788,523.18 in the previous period, reflecting an increase of approximately 34.5%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,093, with the largest shareholder holding 46.14% of the shares[10] - The total number of shares held by the top 10 shareholders is 98,780,906, with a significant portion being subject to lock-up agreements[15] - The largest shareholder, 聂在建, holds 92,946,000 shares, which are subject to a lock-up until August 10, 2025[15] - The company has a total of 127,969 shares released from lock-up during the reporting period[15] Management and Governance - The company plans to use up to RMB 240 million of temporarily idle raised funds for cash management within 12 months from the approval date of the shareholders' meeting[16] - The company intends to utilize up to RMB 100 million of temporarily idle self-owned funds for cash management, also within a 12-month period from the shareholders' meeting approval[17] - The company's management is authorized to make investment decisions within the approved limits for cash management[18] Miscellaneous - The company’s financial reports are prepared as of March 31, 2024, indicating ongoing financial assessments[19] - The first quarter report was not audited, indicating a preliminary financial assessment[28] - The company did not report any net increase in customer deposits or interbank placements during the period[26]

Financial Performance - The company's operating revenue for Q1 2025 was ¥150,204,941.37, a decrease of 21.73% compared to the same period last year[4]. - Net profit attributable to shareholders was ¥24,913,986.70, representing a year-on-year increase of 2.75%[4]. - Total operating revenue for the current period is ¥150,204,941.37, a decrease of 21.8% from ¥191,894,599.16 in the previous period[30]. - Net profit for the current period is ¥24,891,688.68, slightly up from ¥24,247,672.28, indicating a growth of 2.7%[31]. - The total comprehensive income for the current period is ¥24,891,688.68, compared to ¥24,247,672.28 in the previous period, reflecting a growth of 2.7%[32]. Cash Flow - Cash flow from operating activities increased by 83.98% to ¥40,768,366.48, primarily due to a reduction in payments for purchased goods[4][14]. - Operating cash flow net amount increased significantly to ¥40,768,366.48 from ¥22,158,704.92, a growth of 83.9%[34]. - The company reported a significant increase of 4,774.62% in cash flow from investing activities, mainly due to the maturity of large certificates of deposit[14]. - The company experienced a significant increase in cash and cash equivalents, ending the period with ¥1,634,381,193.93, up from ¥95,348,055.91[35]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,751,521,629.28, a decrease of 1.12% from the end of the previous year[5]. - As of March 31, 2025, the company's total current assets amounted to RMB 2,933,444,421.90, a decrease from RMB 3,387,997,986.58 at the beginning of the period[27]. - The company's total non-current assets increased to RMB 1,818,077,207.38 from RMB 1,417,253,752.54[28]. - The total assets of the company as of March 31, 2025, were RMB 4,751,521,629.28, down from RMB 4,805,251,739.12[28]. - The company's total liabilities decreased to RMB 258,898,969.94 from RMB 314,043,539.30[28]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,930[16]. - The largest shareholder, Nie Zaijian, holds 46.31% of the shares, totaling 93,698,770 shares[16]. - The second-largest shareholder, Shandong Luxin Qisheng Investment Management Co., holds 6.62% with 13,400,750 shares[16]. - The total number of restricted shares at the beginning of the period was 99,686,475, with 4,971,975 shares released during the period[19]. - The total number of restricted shares at the end of the period is 94,714,500[20]. - Nie Zaijian's restricted shares will be released on August 10, 2025, totaling 92,946,000 shares[19]. - The company has a total of 1,365,000 restricted shares held by shareholder Nie Yuyue, which will be released on February 10, 2025[20]. - The company has not reported any changes in the top 10 shareholders due to securities lending or borrowing[17]. - The top 10 shareholders include a mix of individual and institutional investors, with significant holdings by private equity funds[16]. - The company has not disclosed any other relationships or agreements among the top shareholders[17]. Research and Development - Research and development expenses decreased by 38.46% compared to the same period last year, as existing projects reached completion and new projects are still under evaluation[13]. - Research and development expenses decreased to ¥9,744,135.17 from ¥15,833,077.03, a reduction of 38.5%[30]. Other Financial Activities - The company is undergoing a correction of prior accounting errors as mandated by the regulatory authority, which will not affect the overall financial position[6]. - The company approved the use of surplus funds amounting to RMB 79,399.00 million for permanent working capital, representing 29.99987% of the total surplus funds[22]. - The company plans to use up to RMB 190,000 million of temporarily idle surplus funds for cash management within 12 months[23]. - The company will continue to use up to RMB 200,000 million of temporarily idle self-owned funds for cash management, also within 12 months[24]. - The company has completed the investment project for an annual production of 50,000 tons of erythritol and will use the surplus funds of RMB 352.2712 million for daily operations[21]. - The company has authorized management to make investment decisions within the approved limits for cash management activities[23]. Earnings Per Share - The company's basic and diluted earnings per share remained unchanged at ¥0.12[4]. - The company reported a basic and diluted earnings per share of ¥0.12, unchanged from the previous period[32]. Audit Status - The company has not undergone an audit for the first quarter report[36].

Financial Performance - The erythritol industry faced unprecedented challenges during the reporting period, leading to oversupply and price declines, which negatively impacted sales revenue and profits[4]. - The company reported a year-on-year decline in both sales revenue and profit due to the dual impact of price and volume[4]. - The company's revenue for 2023 was ¥499,500,775.41, a decrease of 25.99% compared to ¥674,905,595.63 in 2022[22]. - The net profit attributable to shareholders for 2023 was ¥55,981,918.44, down 65.80% from ¥163,686,641.34 in the previous year[22]. - The basic earnings per share for 2023 was ¥0.28, a decline of 65.85% from ¥0.82 in 2022[22]. - The total assets at the end of 2023 amounted to ¥4,807,533,905.12, a decrease of 1.28% from ¥4,869,919,341.29 at the end of 2022[22]. - The net assets attributable to shareholders at the end of 2023 were ¥4,535,129,974.85, down 1.85% from ¥4,620,776,046.41 in 2022[22]. - The cash flow from operating activities for 2023 was ¥57,310,770.18, a decrease of 31.99% compared to ¥84,264,654.04 in 2022[22]. - The weighted average return on equity for 2023 was 1.23%, down from 3.80% in 2022[22]. - The company reported a decrease in net profit after deducting non-recurring gains and losses, which was ¥54,790,117.06 in 2023, down 66.25% from ¥162,331,457.53 in 2022[22]. - The company has experienced a significant decline in both revenue and profit margins over the past year, indicating potential challenges in market performance[22]. Market Trends and Industry Insights - The functional sugar market, particularly erythritol, has seen a compound annual growth rate (CAGR) of 48.9% from 2015 to 2022, indicating rapid industry growth[34]. - China accounted for 78.9% of the global erythritol production in 2022, with a total output of approximately 139,000 tons[34]. - The functional sugar industry is supported by favorable government policies aimed at reducing sugar consumption, creating a conducive environment for growth[42]. - The functional sugar industry in China is experiencing rapid growth, driven by increasing consumer demand for health-oriented, low-sugar, and sugar-free products[44]. - The market size for the sugar-free beverage industry in China is projected to reach approximately 748.9 billion CNY by 2027, with a compound annual growth rate (CAGR) of 38.1% from 2015 to 2023[47]. - Erythritol remains the leading sugar substitute in the zero-sugar and low-sugar beverage market, with widespread acceptance among consumers and regulatory bodies[46]. Product Development and Innovation - The company is focusing on developing functional foods and expanding its product offerings in response to market demands[22]. - The company is actively expanding its market presence by participating in food exhibitions in countries such as the USA, Russia, Brazil, Japan, South Korea, Thailand, and Dubai[97]. - The company is increasing its R&D efforts, focusing on new product development in the functional sugar sector, with products like high-quality stevia, sodium hyaluronate, and tagatose in the pipeline[100]. - The company has developed over 20 varieties of blended sugars, including monk fruit and stevia blends, tailored to customer specifications[59]. - The company has developed key applications for erythritol, including table sugar, beverages, and confectionery, leveraging its natural, near-zero calorie, and pure taste characteristics[61]. - The company is currently developing a fermentation process for rare sugars, which is expected to create new business opportunities[117]. - The company has established a research subsidiary and various research platforms to enhance its innovation capabilities and maintain competitive advantages in product quality and cost[94]. Strategic Initiatives and Future Outlook - The company aims to maintain a market-leading position in erythritol while developing competitive functional sugars and other sugar products, targeting sectors such as special medical foods, cosmetics, and drug delivery systems[148]. - The company plans to adopt a product development strategy of "one generation listed, one generation in research, and one generation in reserve" to ensure a steady pipeline of new products[149]. - The company is committed to enhancing its research and development capabilities by collaborating with leading food fermentation research institutions to diversify its product offerings[150]. - The company plans to increase its workforce by 10% to support the anticipated growth in production and R&D activities[193]. - The management team has emphasized the importance of innovation, with a commitment to allocate 15% of revenue towards R&D initiatives[194]. Governance and Compliance - The company has established a board of directors consisting of 9 members, including 3 independent directors, complying with relevant laws and regulations[166]. - The company has a supervisory board with 3 members, including 1 employee supervisor, ensuring compliance and oversight of major company matters[167]. - The company maintains independence from its controlling shareholders, with no unauthorized use of company funds or interference in decision-making[168]. - The company has implemented a performance evaluation and incentive mechanism for directors and senior management, aligning with its development status[169]. - The company adheres to strict information disclosure practices, ensuring transparency and fairness for all investors[171]. - The internal audit system is effectively implemented, enhancing governance and ensuring the achievement of operational goals[172]. Customer and Market Risks - Erythritol accounted for 81.67% of the company's total revenue in 2023, indicating a risk due to the company's reliance on a single product line[153]. - The top five customers contributed 36.12% of total annual sales, indicating a high customer concentration risk[159]. - The company aims to diversify its customer base and develop new products to mitigate risks associated with major customer changes[159]. - The company recognizes the risk of intensified competition and market demand fluctuations, which could impact sales and pricing of erythritol products[153]. - Raw materials accounted for 63.83% of the main business costs in 2023, with fluctuations in corn prices posing a risk to profitability[155].

三元生物（301206）公告，2025年第一季度营收为1.5亿元，同比下降21.73%；净利润为2491.4万元， 同比增长2.75%。 ...

中信建投证券股份有限公司 关于对山东三元生物科技股份有限公司 2025 年度持续督导的培训报告 深圳证券交易所： 根据《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等相 关法律法规的要求，中信建投证券股份有限公司（以下简称"中信建投"、"保 荐人"）作为山东三元生物科技股份有限公司（以下简称"三元生物"或"公司"） 首次公开发行股票并上市的保荐人及持续督导机构，三元生物项目组成员于 2025 年 4 月 21 日对三元生物公司到场的董事、监事、高级管理人员、中层以上 管理人员及公司控股股东和实际控制人等相关人员进行了专门培训，并对未到场 的相关人员派发了相关培训资料，督促其认真学习培训内容，本次培训的具体情 况如下： 一、培训时间 2025 年 4 月 21 日 二、培训地点 培训地点及形式：三元生物会议室，线下及线上会议培训 三、培训内容 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》等相关规定，进行上市公司股 东减持股份管理规定、募集资金管理和使用的注意事项、新公司法等监管新规动 态的培训，结合相关法律法规和相关案例进行 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 证券代码：301206 证券简称：三元生物 公告编号：2025-029 山东三元生物科技股份有限公司 关于使用暂时闲置超募资金进行现金管理的进展公告 山东三元生物科技股份有限公司（以下简称"公司"）于 2025 年 1 月 24 日 召开了第五届董事会第五次会议和第五届监事会第五次会议，于 2025 年 2 月 10 日召开了 2025 年第二次临时股东大会，上述会议审议通过了《关于使用暂时闲 置超募资金进行现金管理的议案》。同意公司在不影响日常生产经营和保证超募 资金安全使用的前提下，拟使用不超过 190,000 万元人民币暂时闲置超募资金进 行现金管理。使用期限自公司 2025 年第二次临时股东大会会议审议通过之日起 12 个月内有效，在上述投资额度和使用期限内资金可滚动使用。公司授权管理 层在上述额度范围及期限内行使投资决策、签署相关文件等事宜，具体事项由公 司财务部负责组织实施。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于使用暂时闲置超募 ...

证券代码：301206 证券简称：三元生物 公告编号：2025-030 山东三元生物科技股份有限公司 关于变更签字会计师的公告 1 / 2 从事上市公司审计业务，2024 年开始在容诚会计师事务所执业，2022 年开始为 三元生物提供审计服务；近三年签署过多家上市公司审计报告。 （二）诚信记录 签字注册会计师郝光伟近三年因执业行为受到证监会及其派出机构的监督 管理措施的具体情况详见下表： 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2024 年 8 月 29 日 召开了第五届董事会第二次会议和第五届监事会第二次会议，于 2024 年 9 月 18 日召开了第三次临时股东大会，上述会议审议通过了《关于变更会计师事务所的 议案》。同意改聘容诚会计师事务所（特殊普通合伙）（以下简称"容诚会计师事 务所"）为公司 2024 年度审计机构。具体内容详见公司于 2024 年 8 月 30 日在巨 潮资讯网（www.cninfo.com.cn）披露的《关于拟变更会计师事务所的公告》（公 告编号：2024-068）。 近日 ...

证券代码：301206 证券简称：三元生物 公告编号：2025-028 二、其他说明 山东三元生物科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"） 于 2024 年 7 月 8 日 召开了第四届董事会第二十三次会议，会议审议通过了《关于回购公司股份方案 的议案》，同意公司使用自有资金以集中竞价交易方式回购公司已发行的部分人 民币普通股（A 股），用于后期实施股权激励或员工持股计划。本次回购资金总 额不低于人民币 5,000 万元（含），且不超过人民币 10,000 万元（含），回购价格 不超过 35 元/股（含），回购股份的实施期限自公司董事会审议通过回购股份方 案之日起不超过 12 个月，具体回购股份数量以回购结束时实际回购的股份数量 为准。具体内容详见公司于 2024 年 7 月 9 日和 2024 年 7 月 15 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于回购公司股份方案的公告》（公告编号： 2024-045）和《回购报告书》（公告编号： ...

证券代码：301206 证券简称：三元生物 公告编号：2025-027 山东三元生物科技股份有限公司 关于使用暂时闲置超募资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2025 年 1 月 24 日 召开了第五届董事会第五次会议和第五届监事会第五次会议，于 2025 年 2 月 10 日召开了 2025 年第二次临时股东大会，上述会议审议通过了《关于使用暂时闲 置超募资金进行现金管理的议案》。同意公司在不影响日常生产经营和保证超募 资金安全使用的前提下，拟使用不超过 190,000 万元人民币暂时闲置超募资金进 行现金管理。使用期限自公司 2025 年第二次临时股东大会会议审议通过之日起 12 个月内有效，在上述投资额度和使用期限内资金可滚动使用。公司授权管理 层在上述额度范围及期限内行使投资决策、签署相关文件等事宜，具体事项由公 司财务部负责组织实施。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于使用暂时闲置超募 ...